Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures
| Autor: | Jason E. Hawkes, Paulo Reis, Chen-Yen Lin, Talia Muram, William J. Eastman |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Psoriasis and Psoriatic Arthritis. 7:140-149 |
| ISSN: | 2475-5311 2475-5303 |
| Popis: | Background Achieving ≥90% improvement in Psoriasis Area and Severity Index (PASI90) is achievable with newer biologic therapies, such as ixekizumab. Standard of care payment systems such as the Merit-based Incentive Payment System (MIPS) responder criteria could lead to under treatment and lower quality of life (QoL) outcomes compared with PASI90. Objective Show PASI90 is a higher standard than MIPS and is associated with greater improvements in QoL and other PRO outcomes. Methods Patients with moderate-to-severe psoriasis meeting PASI90 and MIPS criteria were compared in 3 phase 3 clinical trials of the interleukin-17A inhibitor ixekizumab (pooled UNCOVER-2/3 and IXORA-S). Patients satisfying MIPS criteria met either static Physician Global Assessment score ≤2, body surface area Results All PASI90 responders were also MIPS responders (PASI90 responders). Not all MIPS responders met PASI90 (MIPS-only responders). Significantly larger change from baseline improvements for all health (skin pain, Itch NRS, DLQI, PtGA, WPAI-PsO work productivity loss, and WPAI-PsO activity impairment) and quality of life (EQ-5D 5L VAS and acute SF-36 PCS/MCS) outcome measures were observed in the PASI90 responders vs the MIPS-only responders. Conclusion PASI90 is a higher standard of response than MIPS and is associated with greater improvements in health and quality of life outcome measures. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|